Bainbridge Island, WA – June 17, 2026 – Solius Labs, the world’s first Personalized UVB Sunlight company, today announced the launch of Solius Pro, the only Food and Drug Administration (FDA)-cleared personalized UVB light therapy device available without a prescription. Solius uses a patent-pending skin analysis system that measures each user's unique skin tone to determine a precise, UVB dose, stimulating the natural health benefits of the sun in approximately five minutes per week. The FDA established a new product code, recognizing Solius as a novel health technology category and placing the company in a distinct regulatory category.
UVB: The Most Powerful Wavelength for Human Health & Longevity
Sunlight is foundational to human health, yet insufficient sunlight exposure has become a significant and growing global health problem. Modern indoor lifestyles, geographic location, and seasonal variation limit access to the UVB wavelengths essential to human health.
UVB is the most powerful and biologically beneficial spectrum of light, but historically has been difficult to dose safely without skin damage, and has largely been limited to dermatologic use under physician supervision. Solius revolutionizes the safety and delivery of UVB light therapy by measuring skin and determining a personalized, safe dose that delivers 12x more UVB biological benefit than the sun with less than 1% total UV risk, now available for home and professional use.
To put this risk into perspective, a full year of once-weekly Solius use delivers less total UV exposure risk than five minutes spent in the afternoon sun. Additionally, Solius delivers 50% less total UV radiation than prescription narrow-band UVB devices.
Beyond Vitamin D: The Systemic Science of Sunlight
A growing body of peer-reviewed research indicates that sunlight is more than a source of vitamin D. When the skin absorbs UVB energy, it converts that energy into hormones and signaling molecules that influence multiple physiological systems and play a key role in fostering a diverse and healthy microbiome.
UVB light has been clinically demonstrated to positively impact mood, energy, cognition, bone health, immune function, cardiovascular health, microbiome, and metabolic resilience.
“Decades of peer-reviewed research confirm that sunlight is fundamental to human health and Vitamin D is a biomarker for UVB exposure," said Chris Kiple, Chief Executive Officer of Solius Labs. "Solius is the first technology to deliver the health benefits of UVB light therapy with dosing personalized to each user’s skin. We are committed to bringing clinically-proven efficacy and an unprecedented standard of safety to the UVB light therapy space.”
FDA Clearance: A New Phototherapy Technology, A New Product Code
The FDA granted clearance for Solius as a Class II medical device under a new FDA product code, SGZ, a UVB light therapy to stimulate the production of Vitamin D, placing it in a distinct regulatory category of its own. This clearance allows Solius to be marketed over-the-counter, expanding access to controlled, clinically validated UVB light therapy year-round.
As the first and only device in its category, Solius enters the market with strong early demand, backed by more than 1,000 pre-orders ahead of launch. Solius is now available to order ($2,995) for both home and professional use at Solius.com.
Personalized Dosing Through Breakthrough Skin Sensing Technology
Achieving the health benefits of sunlight requires a narrow biological sweet spot - enough UVB to activate beneficial processes without causing skin damage.
Solius addresses this challenge with a patent-pending skin analysis and dosing system that evaluates individual skin characteristics and automatically calculates a personalized UVB dose for each user.
Solius therapy is delivered once-weekly to exposed skin on the back. Each session lasts approximately five minutes and is managed through the Solius Mobile App, which includes extensive built-in safety controls to ensure precise, safe delivery for every use.
Clinical Validation and Expert Perspective
In three independent human clinical studies, Solius demonstrated safe delivery of personalized UVB doses without erythema, skin irritation, or adverse events.
In a randomized controlled trial published in Anticancer Research, participants using Solius experienced an average increase of 10 ng/mL in serum vitamin D levels without skin damage or visible tanning, improving their vitamin D status.
“Solius medical UVB light therapy and dosing technology maximize the health benefits of UVB light while nearly eliminating the risks typically associated with sun exposure,” said Dr. Dutz, M.D., Professor and Head of Dermatology at the University of British Columbia, one of the largest phototherapy clinics in North America. “This represents a meaningful advancement in dermatology and medical phototherapy.”
About Solius Labs
Solius Labs is the world’s first Personalized UVB Sunlight company, developing FDA-cleared, medical-grade light technologies that safely replicate the systemic biological benefits of sunlight year-round. By combining a targeted healthy UVB spectrum, personalized dosing, and clinical validation, Solius is redefining how UVB light is used to support human health. For more information, visit Solius.com.